Acute Cholecystitis Associated With the Use of Glucagon-Like Peptide-1 Receptor Agonists Reported to the US Food and Drug Administration

This 2022 pharmacovigilance study analyzed FDA Adverse Event Reporting System (FAERS) data to assess the association between GLP-1 receptor agonists (GLP-1 RAs) and acute cholecystitis. The analysis revealed a notable number of reports linking GLP-1 RAs, such as liraglutide and semaglutide, to cases of acute cholecystitis. The proposed mechanism involves